Navigation Links
David Luci Joins MacroChem as General Counsel and Vice President Corporate Development

Luci Brings Successful Track Record of Building Value in Biotech Arena

Through Experience in Business Development and Investment Community


WELLESLEY HILLS, Mass., Dec. 6 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) has appointed David P. Luci, Esq. as General Counsel and Vice President Corporate Development. Mr. Luci will also be Corporate Secretary with responsibilities encompassing all the company's legal matters including compliance with securities regulations and corporate governance. Included in the scope of Corporate Development activities will be responsibility for partnering activities and investor relations.

"I'm very pleased to welcome David to MacroChem. Having recently completed three very important milestones, we are confident that David's extensive experience will help bolster the company's continued momentum," stated Robert DeLuccia, President and CEO of MacroChem. "These key milestones are: last month's announcement of positive interim Phase 2 data for EcoNail(R) for the treatment of onychomycosis; the recent acquisition of exclusive worldwide license rights to pexiganan, a novel topical anti-infective peptide for the treatment of diabetic foot infection, which has already completed two Phase 3 trials; and the recent conversion of all preferred shares into common shares leaving only common stock, warrants, and options outstanding."

Most recently, Mr. Luci served as Executive Vice President and General Counsel of Bioenvision where he established the company's offices in New York, raised over $75 million in capital, and advanced Bioenvision stock listing from OTCBB to AMEX and then to NASDAQ. He was also responsible for garnering analyst interest for a number of investment firms. While at Bioenvision, he in-licensed the company's development-stage lead cancer drug for Japan and Southeast Asia and initiated drug development activities in Japan. He later successfully guided Bioenvision into a merger agreement and closing of a related tender offer with its U.S. co-development partner, Genzyme, in a transaction valued at approximately $345 million. Prior to joining Bioenvision, Mr. Luci practiced securities law and mergers and acquisitions at Paul, Hastings, Janofsky and Walker LLP, New York. Prior to PHJW, he was Senior Auditor, Ernst and Young, New York, focused on internal audit and controls within the Mergers and Acquisitions Practice Group. He is also a member of the Board of Directors and Chairman of the Audit Committee of Access Pharmaceuticals, Inc.

"David brings a diverse legal, financial, and business background as well as excellent knowledge of the biotech sector, both with pharmaceutical companies and the investment community of our industry," said Mr. DeLuccia. "His experience includes capital markets financing, negotiating deals, and license agreements (both U.S. and ex-U.S.), corporate partnerships, and mergers and acquisitions. I believe this impressive skill set will serve us well as we seek to capitalize on our recent achievements and advance our initiatives in the coming year."

Mr. Luci received his JD, cum laude, from Albany Law School of Union University, Albany, and his Bachelor of Science in Business Administration from Bucknell University. He is a member of the New York Bar Association and a Certified Public Accountant (Pennsylvania).

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website,

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website,


MacroChem: Bernard Patriacca - VP/CFO

(781) 489-7310

Investor Relations: The Investor Relations Group, Inc.

Christine Berni/ Joseph Triunfo, (212) 825-3210


Bill Douglass/ Michaela Heller, (212) 825-3210

SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
3. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
4. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
5. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
6. St. Davids Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders
7. David Grimes, FHI physician, inducted into Institute of Medicine
8. David Kahal Joins AXA Equitable as National Sales Manager
9. Leading Authority on Health Benefits, David Hom, Joins Board of Directors of Healthcare Technology Innovator, NavigatorMD, Inc.
10. Tree named in honor of Virginia Tech chemist David G.I. Kingston
11. Richard Greco Joins Mediware Board
Post Your Comments:
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 , ... ... To incentivize would-be customers, eMarketing Concepts began a $1 promotion – effectively offering all ... a resounding success, and within weeks the company was flooded with phone calls from ...
(Date:10/13/2015)... ... , ... The Bill Howe Family of Companies is an award winning HVAC ... remediation services. Family-owned and operated for 35 years, they have maintained value, ethics and ... two years in a row from the Union Tribune Reader’s Poll, a Healthiest Company ...
(Date:10/12/2015)... ... 2015 , ... Heroes in Recovery (HIR) is proud to ... Network’s Moments of Change conference in West Palm Beach, Florida. Rob Waggener, CEO ... Dauphinais who exemplify the ideals of the Heroes in Recovery movement. , Noah ...
(Date:10/12/2015)... , ... October 12, 2015 , ... Kevin Costello, winner of the “Check-In and Win ... embarks today for his dream vacation to Hawaii. , “I didn’t believe I could win ... says. “This contest encouraged me to get to the gym and invest in my own ...
(Date:10/12/2015)... ... 12, 2015 , ... The American Society of Clinical Hypnosis ... education and clinical training in a health care discipline. , Many practitioners ... as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... Therapy Catapult to advance development of large scale ... immunotherapy. Under the agreement, the Cell Therapy Catapult ... to support advanced clinical trials and eventual commercialization ... --> The Cell Therapy Catapult is a ...
(Date:10/12/2015)... WASHINGTON , Oct. 12, 2015  Former White House ... Press Secretary for the House Narcotics Committee, Robert Weiner ... "Rewriting Drug Policy." The two emphasize that this is now ... Clinton to Jeb Bush , Carly Fiorina ... Sordello cite the newest federal statistics, which they call "a ...
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... 2015, its guidance for the fourth quarter of 2015, ... Senior Secured Credit Facility. --> ...
Breaking Medicine Technology: